Tracking 6 vendors · 83 listings · checked Aug 02Current partner codePEPTIDESDE

ApprovedWeight lossSubcutaneousEvidence 5/5

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

Read full research guide View clinical trials Buy / compare source

This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.

Illustrative profileSubcutaneous

Database profileApproved

SemaglutideWeight loss

Drug class: GLP-1 receptor agonist
Primary targets: GLP-1R
Dose reference: 0.25–2.4 mg once weekly (SC); 3–14 mg daily (oral)
Half-life: ~7 days
Developer / origin: Novo Nordisk
Reference year: 2017
Evidence score: 5/5 - Approved with large human trials

Approved uses

Type 2 diabetes
Chronic weight management
Cardiovascular risk reduction

Evidence 5/5

Approved with large human trials

Semaglutide has large randomized human trials and FDA-regulated labels across diabetes, obesity, and cardiovascular-risk contexts.

Approved medication with substantial human clinical evidence.

Evidence basis

Large human RCTs
FDA-regulated labeling
Approved GLP-1 receptor agonist

Key references

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Semaglutide guides

Read the matching guide or adjacent research pages for more context.

Semaglutide: The GLP-1 That Started It All (Ozempic, Wegovy, Rybelsus)Semaglutide is the GLP-1 receptor agonist behind Ozempic (diabetes), Wegovy (weight loss) and Rybelsus (oral diabetes). Same molecule, three brands, different doses and indications.CagriSema: Cagrilintide + Semaglutide Trial Results, Status and LimitsCagriSema is Novo Nordisk’s investigational amylin + GLP-1 combination. Trial averages look strong, but it is not approved and is not a DIY stack of research vials.Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What WorksA broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.What Is GLP-1? The Hormone, the Drugs, and Why They WorkGLP-1 is a gut hormone released after eating. Agonist drugs amplify that effect — slowing digestion, blunting appetite and steadying blood sugar.

Semaglutide calculator shortcuts

Open peptide calculators with editable Semaglutide example values already filled in.

Semaglutide reconstitution calculatorPrefills a 5 mg vial, 2 mL BAC water and editable dose fields.Open prefilled tool Semaglutide accumulation calculatorPrefills 168 hour half-life and 168 hour interval examples.Open prefilled tool Semaglutide unit converterPrefills 250 mcg with a 5 mg vial example.Open prefilled tool

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open tool Peptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open tool Peptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open tool Peptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5

Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5

Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

Liraglutide

Victoza, Saxenda

5/5

Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

Cagrilintide

AM833

4/5

Weight lossInvestigational

Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Read this first

PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.

Full disclosure →